Shanghai Fosun Pharmaceutical Industrial Development

Shanghai Fosun Pharmaceutical Industrial Development, based in Shanghai, China, is a pharmaceutical company and part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. listed as 600196.SH; 02196.HK. Part of the Fosun Pharma group, a China-rooted global pharmaceutical and healthcare group with operations spanning pharmaceuticals, medical devices, diagnostics, healthcare services and pharmaceutical distribution. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing FCN-159 and Test group (Group A): FCN-159 in non-small-cell lung cancer and rare cancers of childhood. The largest, NCT06569420 (Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC), plans to enrol 275 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.